| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H18FN3 |
| Molecular Weight | 283.3433 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(N1C=C(C)C2=C1C=CC=C2)C3=C(F)C=NC=C3
InChI
InChIKey=BTDHTARYCBHHPJ-UHFFFAOYSA-N
InChI=1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3
| Molecular Formula | C17H18FN3 |
| Molecular Weight | 283.3433 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Nerispirdine, an acetylcholine release enhancer and a K+/Na+ use-dependent channel blocker, was in clinical development with sanofi-aventis for the treatment of multiple sclerosis. Nerispirdine is not proconvulsant. It can inhibit axonal K(+) channels and this mechanism may underlie the ability of the drug to enhance neuronal conduction. Nerispirdine can also inhibit neuronal Na(+) channels, a mechanism that may explain why nerispirdine lacks proconvulsant activity.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
Visual function in patients with multiple sclerosis: single oral doses of 50 mg and 400 mg Nerispirdine
Route of Administration:
Oral
